These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 9857387

  • 21. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
    Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA.
    Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
    [Abstract] [Full Text] [Related]

  • 22. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
    Trapp OM, Beykirch MK, Petrides PE.
    Blood Cells Mol Dis; 1998 Mar; 24(1):9-13. PubMed ID: 9516377
    [Abstract] [Full Text] [Related]

  • 23. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.
    N Engl J Med; 2005 Jul 07; 353(1):33-45. PubMed ID: 16000354
    [Abstract] [Full Text] [Related]

  • 24. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
    Petrides PE, Beykirch MK, Trapp OM.
    Eur J Haematol; 1998 Aug 07; 61(2):71-6. PubMed ID: 9714517
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results.
    Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F.
    Haematologica; 1992 Aug 07; 77(4):315-7. PubMed ID: 1427441
    [Abstract] [Full Text] [Related]

  • 32. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
    Bennett M.
    Harefuah; 1999 May 02; 136(9):717-20. PubMed ID: 10955097
    [No Abstract] [Full Text] [Related]

  • 33. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN, Tefferi A.
    Semin Hematol; 1999 Jan 02; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
    Thiele J, Kvasnicka HM, Schmitt-Gräff A.
    Pathologe; 2002 Nov 02; 23(6):426-32. PubMed ID: 12436295
    [Abstract] [Full Text] [Related]

  • 39. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT.
    Leukemia; 2005 Jan 02; 19(1):39-43. PubMed ID: 15510207
    [Abstract] [Full Text] [Related]

  • 40. Long-term use of anagrelide in young patients with essential thrombocythemia.
    Storen EC, Tefferi A.
    Blood; 2001 Feb 15; 97(4):863-6. PubMed ID: 11159509
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.